© 2017 American Society for Microbiology. ß-Lactam/ß-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum- ß-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenemsparing alternatives for the treatment of BSI due to ESBLs in these patients.
|Journal||Antimicrobial Agents and Chemotherapy|
|Publication status||Published - 1 Aug 2017|
- Beta-lactam/beta-lactamase inhibitors
- Bloodstream infection